Logo image of SCNI

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Stock Price, Quote, News and Overview

NASDAQ:SCNI - Nasdaq - US09073Q3039 - ADR - Currency: USD

3.52  +0.14 (+4.28%)

SCNI Quote, Performance and Key Statistics

SCINAI IMMUNOTHERAPEUTICS LT

NASDAQ:SCNI (2/21/2025, 8:00:01 PM)

3.52

+0.14 (+4.28%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High8.92
52 Week Low2.23
Market Cap3.00M
Shares853.00K
Float752.65K
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO06-07 2007-06-07


SCNI short term performance overview.The bars show the price performance of SCNI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10

SCNI long term performance overview.The bars show the price performance of SCNI in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of SCNI is 3.52 USD. In the past month the price decreased by -0.62%. In the past year, price decreased by -28.16%.

SCINAI IMMUNOTHERAPEUTICS LT / SCNI Daily stock chart

SCNI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About SCNI

Company Profile

SCNI logo image Scinai Immunotherapeutics Ltd is a IL-based company operating in Biotechnology industry. Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Company Info

SCINAI IMMUNOTHERAPEUTICS LT

Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus

JERUSALEM IL

Employees: 31

Company Website: https://www.scinai.com/

Investor Relations: http://www.biondvax.com/investors/

Phone: 97289302529

SCINAI IMMUNOTHERAPEUTICS LT / SCNI FAQ

What is the stock price of SCINAI IMMUNOTHERAPEUTICS LT today?

The current stock price of SCNI is 3.52 USD. The price increased by 4.28% in the last trading session.


What is the ticker symbol for SCINAI IMMUNOTHERAPEUTICS LT stock?

The exchange symbol of SCINAI IMMUNOTHERAPEUTICS LT is SCNI and it is listed on the Nasdaq exchange.


On which exchange is SCNI stock listed?

SCNI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SCINAI IMMUNOTHERAPEUTICS LT stock?

7 analysts have analysed SCNI and the average price target is 714 USD. This implies a price increase of 20184.09% is expected in the next year compared to the current price of 3.52. Check the SCINAI IMMUNOTHERAPEUTICS LT stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SCINAI IMMUNOTHERAPEUTICS LT worth?

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a market capitalization of 3.00M USD. This makes SCNI a Nano Cap stock.


How many employees does SCINAI IMMUNOTHERAPEUTICS LT have?

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) currently has 31 employees.


What are the support and resistance levels for SCINAI IMMUNOTHERAPEUTICS LT (SCNI) stock?

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a support level at 3.51 and a resistance level at 3.79. Check the full technical report for a detailed analysis of SCNI support and resistance levels.


Should I buy SCINAI IMMUNOTHERAPEUTICS LT (SCNI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SCINAI IMMUNOTHERAPEUTICS LT (SCNI) stock pay dividends?

SCNI does not pay a dividend.


What is the Price/Earnings (PE) ratio of SCINAI IMMUNOTHERAPEUTICS LT (SCNI)?

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.7).


What is the Short Interest ratio of SCINAI IMMUNOTHERAPEUTICS LT (SCNI) stock?

The outstanding short interest for SCINAI IMMUNOTHERAPEUTICS LT (SCNI) is 0.05% of its float. Check the ownership tab for more information on the SCNI short interest.


SCNI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to SCNI. When comparing the yearly performance of all stocks, SCNI is a bad performer in the overall market: 80.91% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SCNI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to SCNI. SCNI has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SCNI Financial Highlights

Over the last trailing twelve months SCNI reported a non-GAAP Earnings per Share(EPS) of -18.7. The EPS increased by 108.9% compared to the year before.


Industry RankSector Rank
PM (TTM) 561.28%
ROA 20.69%
ROE 25.36%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)108.9%
Revenue 1Y (TTM)N/A

SCNI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to SCNI. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners13.75%
Ins Owners7.62%
Short Float %0.05%
Short Ratio0.03
Analysts
Analysts82.86
Price Target714 (20184.09%)
EPS Next Y98.91%
Revenue Next YearN/A